{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T01:37:18Z","timestamp":1794101838348,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s12325-023-02559-1","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T23:28:44Z","timestamp":1687562924000},"page":"3770-3783","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia\u00a0B Switched from Standard Half-Life Therapy in Three European Countries"],"prefix":"10.1007","volume":"40","author":[{"given":"Eva","family":"Funding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-9557","authenticated-orcid":false,"given":"Gillian","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone H.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0402-0802","authenticated-orcid":false,"given":"Susan","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-242X","authenticated-orcid":false,"given":"Daniel","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aletta","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4717-5855","authenticated-orcid":false,"given":"Carly","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"issue":"Suppl. 6","key":"2559_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl. 6):1\u2013158.","journal-title":"Haemophilia"},{"issue":"6","key":"2559_CR2","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/ejh.13055","volume":"100","author":"TW Buckner","year":"2018","unstructured":"Buckner TW, Witkop M, Guelcher C, et al. Impact of hemophilia\u00a0B on quality of life in affected men, women, and caregivers\u2014assessment of patient-reported outcomes in the B-HERO-S study. Eur J Haematol. 2018;100(6):592\u2013602.","journal-title":"Eur J Haematol"},{"issue":"3","key":"2559_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/hae.14525","volume":"28","author":"E Berntorp","year":"2022","unstructured":"Berntorp E, LeBeau P, Ragni MV, et al. Quality of life in a large multinational haemophilia\u00a0B cohort (The B-Natural study)\u2014unmet needs remain. Haemophilia. 2022;28(3):453\u201361.","journal-title":"Haemophilia"},{"issue":"3","key":"2559_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3324\/haematol.2019.232132","volume":"105","author":"PM Mannucci","year":"2020","unstructured":"Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545\u201353.","journal-title":"Haematologica"},{"key":"2559_CR5","unstructured":"European Medicines Agency. Alprolix\u00ae Summary of Product Characteristics 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alprolix-epar-product-information_en.pdf. Accessed 23 Mar 2023."},{"key":"2559_CR6","unstructured":"Bioverativ Therapeutics Inc. Alprolix\u00ae Prescribing Information 2020. http:\/\/products.sanofi.us\/Alprolix\/alprolix.pdf. Accessed 23 Mar 2023."},{"issue":"24","key":"2559_CR7","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","volume":"369","author":"JS Powell","year":"2013","unstructured":"Powell JS, Pasi KJ, Ragni MV, et al. Phase\u00a03 study of recombinant factor\u00a0IX Fc fusion protein in hemophilia\u00a0B. N Engl J Med. 2013;369(24):2313\u201323.","journal-title":"N Engl J Med"},{"issue":"2","key":"2559_CR8","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/S2352-3026(16)30193-4","volume":"4","author":"K Fischer","year":"2017","unstructured":"Fischer K, Kulkarni R, Nolan B, et al. Recombinant factor\u00a0IX Fc fusion protein in children with haemophilia\u00a0B (Kids B-LONG): results from a multicentre, non-randomised phase\u00a03 study. Lancet Haematol. 2017;4(2):e75\u201382.","journal-title":"Lancet Haematol"},{"issue":"1","key":"2559_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/bjh.13109","volume":"168","author":"J Powell","year":"2015","unstructured":"Powell J, Shapiro A, Ragni M, et al. Switching to recombinant factor\u00a0IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor\u00a0IX consumption and lower bleeding rates. Br J Haematol. 2015;168(1):113\u201323.","journal-title":"Br J Haematol"},{"issue":"1","key":"2559_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/hae.14455","volume":"28","author":"J Astermark","year":"2022","unstructured":"Astermark J, Hermans C, Ezzalfani M, et al. rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia\u00a0B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires. Haemophilia. 2022;28(1):18\u201326.","journal-title":"Haemophilia"},{"issue":"6","key":"2559_CR11","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1111\/hae.14036","volume":"26","author":"KJ Pasi","year":"2020","unstructured":"Pasi KJ, Fischer K, Ragni M, et al. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor\u00a0IX Fc fusion protein in subjects with haemophilia\u00a0B: results from the B-YOND extension study. Haemophilia. 2020;26(6):e262\u201371.","journal-title":"Haemophilia"},{"issue":"13","key":"2559_CR12","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/bloodadvances.2020004085","volume":"5","author":"B Nolan","year":"2021","unstructured":"Nolan B, Klukowska A, Shapiro A, et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia\u00a0B. Blood Adv. 2021;5(13):2732\u20139.","journal-title":"Blood Adv"},{"issue":"7","key":"2559_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12602","volume":"5","author":"M O'Donovan","year":"2021","unstructured":"O\u2019Donovan M, Quinn E, Johnston K, et al. Recombinant factor\u00a0IX-Fc fusion protein in severe hemophilia\u00a0B: patient-reported outcomes and health-related quality of life. Res Pract Thromb Haemost. 2021;5(7):e12602.","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2559_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/hae.14307","volume":"27","author":"M O'Donovan","year":"2021","unstructured":"O\u2019Donovan M, Bergin C, Quinn E, et al. Real-world outcomes with recombinant factor\u00a0IX Fc fusion protein (rFIXFc) prophylaxis: longitudinal follow-up in a national adult cohort. Haemophilia. 2021;27(4):618\u201325.","journal-title":"Haemophilia"},{"issue":"6","key":"2559_CR15","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1111\/hae.14426","volume":"27","author":"M O'Donovan","year":"2021","unstructured":"O\u2019Donovan M, Singleton E, Roche S, et al. Single centre, real-world experience of perioperative rFIXFc use in adult patients with haemophilia\u00a0B undergoing major and minor surgery. Haemophilia. 2021;27(6):e690\u20137.","journal-title":"Haemophilia"},{"issue":"5","key":"2559_CR16","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/hae.14585","volume":"28","author":"AE Lehtinen","year":"2022","unstructured":"Lehtinen AE, Baghaei F, Astermark J, Holme PA. Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: real-world experience in the Nordic countries. Haemophilia. 2022;28(5):713\u20139.","journal-title":"Haemophilia"},{"issue":"6","key":"2559_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/hae.14152","volume":"26","author":"A Shapiro","year":"2020","unstructured":"Shapiro A, Chaudhury A, Wang M, et al. Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia\u00a0B after switching to recombinant factor\u00a0IX Fc fusion protein (rFIXFc) for up to 5 years. Haemophilia. 2020;26(6):975\u201383.","journal-title":"Haemophilia"},{"issue":"6","key":"2559_CR18","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/hae.13834","volume":"25","author":"F Peyvandi","year":"2019","unstructured":"Peyvandi F, Garagiola I, Boscarino M, Ryan A, Hermans C, Makris M. Real-life experience in switching to new extended half-life products at European haemophilia centres. Haemophilia. 2019;25(6):946\u201352.","journal-title":"Haemophilia"},{"issue":"3","key":"2559_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/hae.13970","volume":"26","author":"Y Brennan","year":"2020","unstructured":"Brennan Y, Parikh S, McRae S, Tran H. The Australian experience with switching to extended half-life factor VIII and IX concentrates: on behalf of the Australian Haemophilia Centre Directors\u2019 Organisation. Haemophilia. 2020;26(3):529\u201335.","journal-title":"Haemophilia"},{"issue":"2","key":"2559_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/hae.13936","volume":"26","author":"A Rampotas","year":"2020","unstructured":"Rampotas A, Desborough MJR, Raza-Burton S, et al. A single centre retrospective study of low dose prophylaxis with extended half-life factor\u00a0IX for severe haemophilia\u00a0B. Haemophilia. 2020;26(2):278\u201381.","journal-title":"Haemophilia"},{"key":"2559_CR21","unstructured":"International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP). Revision 3: June 2015. https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/. Accessed 23 Mar 2023."},{"issue":"11","key":"2559_CR22","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935\u20139.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2559_CR23","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1007\/s12325-020-01300-6","volume":"37","author":"C Hermans","year":"2020","unstructured":"Hermans C, Marino R, Lambert C, et al. Real-world utilisation and bleed rates in patients with haemophilia\u00a0B who switched to recombinant factor\u00a0IX fusion protein (rIX-FP): a retrospective international analysis. Adv Ther. 2020;37(6):2988\u201398.","journal-title":"Adv Ther"},{"issue":"1","key":"2559_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/03007995.2019.1662675","volume":"36","author":"J Oldenburg","year":"2020","unstructured":"Oldenburg J, Yan S, Maro G, Krishnarajah G, Tiede A. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia\u00a0B patients treated with extended half-life rIX-FP compared to prior drug therapy. Curr Med Res Opin. 2020;36(1):9\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2559_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/03007995.2021.1991901","volume":"38","author":"M van der Sluijs","year":"2022","unstructured":"van der Sluijs M, Huyghe N, Wood C, Tawil S. A survey of physicians\u2019 treatment switching practice in people on long-term prophylaxis for hemophilia in five European countries. Curr Med Res Opin. 2022;38(1):65\u201373.","journal-title":"Curr Med Res Opin"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02559-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02559-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02559-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:17:21Z","timestamp":1692112641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02559-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2559"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02559-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,23]]},"assertion":[{"value":"14 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}